3004.90.92.18 - Containing diltiazem or its salts 🖩

This HTS classification, 3004.90.92.18, specifically covers pharmaceutical products in measured doses or retail packaging for therapeutic or prophylactic use that contain diltiazem or its salts. Diltiazem is a widely used medication belonging to the calcium channel blocker class, primarily prescribed for the treatment of hypertension, angina (chest pain), and certain heart rhythm disorders. The classification applies regardless of whether the diltiazem is present as the active pharmaceutical ingredient alone or in combination with other inactive ingredients, provided the final product meets the criteria of a medicament.

This category is distinguished from its sibling categories by the specific active pharmaceutical ingredient it contains. For instance, 3004.90.92.16 covers medicaments containing metoprolol, a beta-blocker, while 3004.90.92.17 pertains to those containing amiodarone, an antiarrhythmic. Similarly, 3004.90.92.19 is for hydralazine-containing products. This sub-classification ensures accurate tariff application based on the precise pharmacological agent responsible for the intended therapeutic effect, allowing customs officials to differentiate between drugs with distinct medical uses and, potentially, different regulatory or tariff treatments.

As a leaf node, this classification does not have further subcategories. Therefore, the focus remains on identifying medicaments where diltiazem or its salts are the primary or a significant active component. The classification is determined by the presence of diltiazem, irrespective of its dosage form (e.g., tablets, capsules, injectables) or the specific salt form (e.g., hydrochloride). The key criterion is the identification of diltiazem as the active constituent within a product intended for medical treatment or prevention.